Warning: UK E-liquids may Contain Dangerous Synthetic Drugs

Regulations by 2FIRSTS.ai
Feb.08.2024
Warning: UK E-liquids may Contain Dangerous Synthetic Drugs
Warning: Some e-liquids sold in the UK may contain illicit substances, including synthetic cannabinoids known as "spice."

Recently, health experts in Wales, UK issued a warning claiming that e-liquids being sold in the country may contain synthetic marijuana compounds known as "Spice". They argue that these illicit e-liquids have extremely potent medicinal effects and pose a danger to users who opt for counterfeit prescription drug e-cigarette products.

 

Some e-liquids consumed by UK consumers in their daily lives contain cannabis, CBD, or tetrahydrocannabinol (THC). Recently, WEDINOS, the only nationwide drug testing service in the UK, conducted tests and found that certain e-liquids being sold in the market also contain a potent synthetic drug known as synthetic cannabinoid receptor agonists (SCRAs), sometimes referred to as "spice." Based on these test results, the Welsh public health department has stated that some of these products being sold in the UK pose significant risks to consumers.

 

Synthetic cannabinoid receptor agonists (SCRAs) are a group of compounds associated with significant health issues, ranging from respiratory difficulties to psychiatric episodes. The latest data from WEDINOS, an organization, reveals that out of the 196 liquid samples submitted to them in 2023, 75 samples (almost one-third) contained one or more SCRA compounds.

 

These samples were purchased in the form of cannabis, CBD, or THC e-liquids. Among the number of hospitalizations due to illicit drugs, opioids are the most prevalent, followed by cannabis and synthetic cannabinoids such as Spice. Opioids also remain the most likely type of drug to be associated with drug-related deaths.

 

Experts from the agency have expressed concern over a significant increase in the number of counterfeit prescription drug samples they have received, which have been contaminated with potentially hazardous substances. They have also frequently detected the presence of benzodiazepines, a class of drugs commonly purchased as prescription medication, such as diazepam and hydrocodone.

 

These highly concentrated synthetic opioid medications can pose a threat to life, and there is a significant risk of overdosing. Last year, WEDINOS received 90 samples containing nitrous nitrogen drugs, with nearly 50% purchased under the mistaken belief of being an anti-anxiety medication called diazepam.

 

Professor Rick Lines, the Head of Drug Abuse at the Welsh Public Health Department, has highlighted the need to recognize the increased risk of medication overdose associated with high-concentration drugs. "Our concern is that people who purchase e-cigarettes online may not actually be receiving what they believe they are getting," he cautioned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny
Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.
Dec.02 by 2FIRSTS.ai
Kyrgyzstan Extends Import Ban on E-Cigarettes and Nicotine Liquids by Six Months
Kyrgyzstan Extends Import Ban on E-Cigarettes and Nicotine Liquids by Six Months
The Kyrgyz government has extended its ban on the import of electronic cigarettes and nicotine-containing liquids for another six months. The decision, signed by the chairman of the Cabinet of Ministers, covers e-cigarettes, integrated nicotine delivery systems, and nicotine liquids used in such devices. The original ban was introduced in July and was due to expire soon.
Dec.24 by 2FIRSTS.ai
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria Group, Inc. (NYSE: MO) announced that CEO Billy Gifford will retire at the conclusion of the 2026 Annual Meeting of Shareholders on May 14, 2026, after more than 30 years with the company. The Board of Directors has elected Salvatore (Sal) Mancuso, Altria’s current Executive Vice President and CFO, to succeed him as CEO.
Dec.12 by 2FIRSTS.ai
Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
DOJO has launched the upgraded BLAST 30K PRO on its official website. The device features a (2+8) ml ×2 “2 ml prefilled pod + 8 ml refill” configuration, delivering 20 ml of e-liquid per kit and claiming up to 30,000 puffs. It is also labeled as fully compatible with BLAST 10K Pods.
Jan.12 by 2FIRSTS.ai
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia MOH: 25,643 enforcement operations and 496,247 premises inspected nationwide as of Nov. 30
Malaysia’s Ministry of Health said it conducted 25,643 enforcement operations involving inspections of 496,247 premises nationwide as of Nov.
Jan.09 by 2FIRSTS.ai
2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts hosted “Decisive 2026” in Shenzhen, bringing together industry perspectives to examine major shifts in the U.S. new tobacco market in 2025 and their global implications. Sessions covered U.S. market dynamics, technical insights from recently PMTA-authorized products, an investor lens on tobacco capital markets, and 2025 news/product highlights. The event underscored a structural shift from “gray business” toward compliance and sustainable growth, expected to become clearer by 2026.
Jan.09